Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Beacon Tactical Alternatives Risk ETF
BlackRock Investment Quality Municipal Trust Inc. (The)
BlackRock Municipal Income Fund, Inc. Common Stock
BlackRock Municipal Income Trust II
BlackRock Virginia Municipal Bond Trust
Blackrock MuniHoldings California Quality Fund, Inc. Common Stock
Blackrock MuniHoldings Fund, Inc. Common Stock
Blackrock MuniHoldings Investment Quality Fund Common Shares of Beneficial Inter
Blackrock MuniHoldings New Jersey Quality Fund, Inc. Common Stock
Blackrock MuniVest Fund II, Inc. Common Stock
Blackrock MuniVest Fund, Inc. Common Stock
Blackrock MuniYield California Fund, Inc. Common Stock
Blackrock MuniYield California Quality Fund, Inc. Common Stock
Blackrock MuniYield Fund, Inc. Common Stock
Blackrock MuniYield New Jersey Fund, Inc Common Stock
Blackrock MuniYield Quality Fund III, Inc Common Stock
Blackrock MuniYield Quality Fund, Inc. Common Stock
Blackrock Municipal Income Quality Trust Common Shares of Beneficial Interest
Exro Technologies Inc
Kindly MD, Inc. - Warrants
SLM Corporation - Floating Rate Non-Cumulative Preferred Stock, Series B
Skye Bioscience, Inc. - Common Stock
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Dyne Therapeutics, Inc.
< Previous
1
2
3
4
Next >
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 19, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Participate in Upcoming Investor Conference
November 11, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 05, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 22, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
September 29, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
September 08, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
September 03, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Participate in Upcoming Investor Conferences
September 02, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 29, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
July 28, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
July 23, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
July 21, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
July 21, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
July 20, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
June 17, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
HTGC
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
June 03, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
May 20, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
April 27, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
April 01, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
March 08, 2026
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.